Descemet Endothelial Thickness Comparison Trials (DETECT I & II)

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on endothelial cell loss.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Dysfunctional endothelium from Fuchs Endothelial Corneal Dystrophy (FECD) with guttata extending beyond 4.5 mm of the central cornea or severe edema without visualization of guttata

• Dysfunctional endothelium from Pseudophakic Corneal Edema (PCE) or Iridocorneal Endothelial Syndrome (ICE) or other primary endothelial dysfunction such as Posterior Polymorphous Corneal Dystrophy (PPMD)

• Dysfunctional endothelium from prior graft failure after PKP or EK

• Controlled uveitis (defined as quiet for \> 3 months off of topical steroids with or without systemic immunosuppression) or no uveitis

• Controlled glaucoma with topical medications and/or prior trabeculectomy or tube shunt without ongoing hypotony (IOP \< 5 mmHg) or no glaucoma

• Good candidate for corneal transplantation for either DMEK or UT-DSAEK

• Willingness to participate

• Age greater than 18 years

Locations
United States
California
Stanford University
RECRUITING
Palo Alto
University of California Davis
RECRUITING
Sacramento
Florida
University of Miami
RECRUITING
Palm Beach Gardens
New Hampshire
Dartmouth-Hitchcock Medical Center
RECRUITING
Lebanon
Oregon
Oregon Health & Science University
RECRUITING
Portland
Pennsylvania
University of Pennsylvania
RECRUITING
Philadelphia
Wills Eye Hospital
RECRUITING
Philadelphia
Contact Information
Primary
Nicole Varnado, MPH
nvarnado@stanford.edu
650-725-1688
Backup
Maalika Kanchugantla, MPH
maalikaa@stanford.edu
Time Frame
Start Date: 2022-07-15
Estimated Completion Date: 2027-11-30
Participants
Target number of participants: 160
Treatments
Experimental: UT-DSAEK plus topical ripasudil
This arm will receive UT-DSAEK plus topical ripasudil 0.4%
Placebo_comparator: UT-DSAEK plus topical placebo
This arm will receive UT-DSAEK plus topical placebo
Experimental: DMEK plus topical ripasudil
This arm will receive DMEK plus topical ripasudil 0.4%
Placebo_comparator: DMEK plus topical placebo
This arm will receive DMEK plus topical placebo
Related Therapeutic Areas
Sponsors
Leads: Stanford University
Collaborators: University of Miami, Wills Eye Hospital, Oregon Health and Science University, Dartmouth-Hitchcock Medical Center, Case Western Reserve University, University of California, Davis, University of California, San Francisco, University of Pennsylvania

This content was sourced from clinicaltrials.gov